Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study. - Wikidata - awgldk - TriplyDB

Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.

Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.

http://www.wikidata.org/entity/Q33390600

about

New molecular targets in mantle cell lymphoma New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)Advances in the clinical development of heat shock protein 90 (Hsp90) inhibitors in cancers The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage Developing a library of authenticated Traditional Chinese Medicinal (TCM) plants for systematic biological evaluation--rationale, methods and preliminary results from a Sino-American collaboration.The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1.Molecular targeted approaches in mantle cell lymphoma.Multi-drug delivery to tumor cells via micellar nanocarriers Hsp90 molecular chaperone inhibitors: are we there yet?Tipifarnib and tanespimycin show synergic proapoptotic activity in U937 cells Unfolded protein response in cancer: the physician's perspective Molecular-targeted nanotherapies in cancer: enabling treatment specificity.Hypoxia inducible factor pathway inhibitors as anticancer therapeutics.Heat shock protein 90 and role of its chemical inhibitors in treatment of hematologic malignancies Heat shock proteins in multiple myeloma The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma.Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX.A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma.[Predictive molecular pathological stratification of hematological neoplasms].

P2860

Q26821766-38E7383A-5C8F-43D2-A32F-72869910EF85 Q27004421-0DD104C4-5102-4922-AA15-F8A4134AD6EB Q27022514-22033824-FEF2-45E8-83D2-99BB2D6A0C97 Q28730558-667EC76E-6449-4BCA-8E40-583DA811EE42 Q30498042-91844E92-1631-43D3-BD52-525D28F3B8DD Q34282588-DFBCB240-266C-49EA-99B2-992E5438C24B Q35127368-954A3D19-E6D2-49B2-8F6E-A2514391C3C5 Q35269272-730D6F8B-EC14-4A2A-B842-591AC6EE2E70 Q35655105-FAE7409F-22C9-4CBB-9880-CB57279580ED Q35754391-5CAAEB33-86F0-48FB-AFB9-40E5E6575D4C Q37846249-3BC1C3FA-C606-4392-8CE4-284B0C0BFA53 Q37954497-F5BC2213-18AA-4D25-93B2-D4F80E2F4091 Q38097867-09B79AD3-96BB-4F6E-9683-95CFCDD0068B Q38166527-219721AF-F0F8-4B21-8FEA-6FD2F34007BD Q38199919-EE28A7A9-7897-4E5D-A896-15389B9F071B Q41470772-CE470A57-EA9A-41AB-BB7E-BAF4E58BBD76 Q42770281-3DA6BE6B-984A-4D50-BB3B-4F64E2D8EAAB Q47105068-5BAA7A58-52BB-4FEF-A393-D39B46F883BA Q53031103-6CEE34FE-7B72-45FA-9FB8-35942C09C140

P2860

Tanespimycin monotherapy in relapsed multiple myeloma: results of a phase 1 dose-escalation study.

http://www.wikidata.org/entity/Q33390600

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Tanespimycin monotherapy in re ...... phase 1 dose-escalation study.

@ast

Tanespimycin monotherapy in re ...... phase 1 dose-escalation study.

@en

type

label

Tanespimycin monotherapy in re ...... phase 1 dose-escalation study.

@ast

Tanespimycin monotherapy in re ...... phase 1 dose-escalation study.

@en

prefLabel

Tanespimycin monotherapy in re ...... phase 1 dose-escalation study.

@ast

Tanespimycin monotherapy in re ...... phase 1 dose-escalation study.

@en

P1433

Q33390600-ACF4CE7F-379E-4227-B6DD-F85F30F3F46D

P1476

Q33390600-AA646914-CD61-4C12-86FD-BD4BA03B8C27

P2093

Q33390600-35937769-BAF6-4793-B268-C2DEF45527C2

Q33390600-4891C9AF-FAF7-456F-A96D-A38D5F20FB6B

Q33390600-676CE36A-5FE7-4ACA-BC08-5976DD148A98

Q33390600-AFE82AA8-D46D-43C2-83A7-1DABD11B4DB3

Q33390600-C026CDB9-4C08-4489-861B-427DF842F484

Q33390600-D375805F-2729-47E9-A5DC-773D3BAAC320

Q33390600-DEC61687-1B5B-4447-9396-F064D8F525CE

P2860

Q33390600-1B7B152D-BE27-429B-B640-DB3C915E690D

Q33390600-1E83C4F2-AA5A-442B-9AD0-9992E1730A0B

Q33390600-3773521F-C38B-4A2E-9AFD-7E706EB8E28E

Q33390600-5EB77555-5887-4241-82D0-63B0BE31D08C

Q33390600-622B95DB-1623-4A49-8856-7BA94FE98576

Q33390600-79522826-7FDE-48AF-B1A7-2BF73726DD95

Q33390600-93270E66-5B9A-4E3A-BD4F-62D17AFC5CD0

Q33390600-9730ECD4-1588-4B5C-B5F9-1E1593535060

Q33390600-A991E28A-AF4C-4958-B2FB-13DFF84C1477

Q33390600-B62C2D63-650E-4055-946E-3A441E3A11E2

P304

Q33390600-D6CAAA75-8B14-46B4-8B0C-5110F2EB57AE

P31

Q33390600-E52AFB11-8A7A-4587-A090-0126ABE44C05

P356

Q33390600-BBE3562F-5FB0-475A-B6A6-96DE5FD0DDD4

P407

Q33390600-15939279-749A-44D9-99F1-E9AF750565A0

P433

Q33390600-44D8DE60-D95F-429D-AACB-12C7A6BE8935

P478

Q33390600-512317B9-862C-42B5-81CB-038C96B627EA

P50

Q33390600-5A006D5D-AF8E-4C4D-AF16-CFF8890AFB2F

P577

Q33390600-E933649C-6D29-487A-8B83-99976980063A

P5875

Q33390600-FDF25D8C-3BB3-44C5-9610-5CCA05680C28

P698

Q33390600-83994EEF-44B9-4D83-865B-7FFDAEF9101B

P932

Q33390600-A43579C8-AE4E-49C5-B84E-925CEEBD4529

P356

J.1365-2141.2010.08265.X

P1433

British Journal of Haematology

P1476

Tanespimycin monotherapy in re ...... phase 1 dose-escalation study.

@en

P2093

Asher A Chanan-Khan

http://www.w3.org/2001/XMLSchema#string

Constantine S Mitsiades

http://www.w3.org/2001/XMLSchema#string

David Berman

http://www.w3.org/2001/XMLSchema#string

Kenneth C Anderson

http://www.w3.org/2001/XMLSchema#string

Marianne Messina

http://www.w3.org/2001/XMLSchema#string

Melissa Alsina

http://www.w3.org/2001/XMLSchema#string

Paul G Richardson

http://www.w3.org/2001/XMLSchema#string

P2860

HSP90 and the chaperoning of cancer

A phase 2 study of bortezomib in relapsed, refractory myeloma.

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma.

Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers.

Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression.

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.

Clinical development of 17-allylamino, 17-demethoxygeldanamycin.

Molecular sequelae of proteasome inhibition in human multiple myeloma cells

Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant.

P304

438-445

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2010.08265.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

150

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-07-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45147484

http://www.w3.org/2001/XMLSchema#string

P698

20618337

http://www.w3.org/2001/XMLSchema#string

P932

3126095

http://www.w3.org/2001/XMLSchema#string